Volume 6.22 | Jun 12

Mammary Cell News 6.22 June 12, 2014
Mammary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
New Test Predicts if Breast Cancer Will Spread
A test that counts the number of locations in tumor specimens where tumor cells may invade blood vessels predicted the risk of distant spread, or metastasis, for the most common type of breast cancer. The test proved more accurate in predicting the risk of distant tumor spread than a test closely resembling the leading breast cancer prognostic indicator on the market. [Press release from Albert Einstein College of Medicine discussing online prepublication in the Journal of National Cancer Institute] Press Release | Abstract
Learn More: Column-Free Enrichment of Mouse Mammary Stem & Progenitor Cells
PUBLICATIONS (Ranked by impact factor of the journal)

MicroRNA-205 Signaling Regulates Mammary Stem Cell Fate and Tumorigenesis
Knockdown of microRNA-205 in mammary epithelial cells promoted epithelial-mesenchymal transition, disrupted epithelial cell polarity, and enhanced symmetric division to expand the stem cell population. [J Clin Invest] Full Article

CXCL12-γ in Primary Tumors Drives Breast Cancer Metastasis
To investigate the effects of chemokine C-X-C motif chemokine ligand 12 (CXCL12) isoforms on tumor growth and metastasis, researchers used a mouse xenograft model of metastatic human breast cancer combining CXCR4+ breast cancer cells and mammary fibroblasts secreting an isoform of CXCL12. [Oncogene] Abstract

Mammary Glands Exhibit Molecular Laterality and Undergo Left-Right Asymmetric Ductal Epithelial Growth in MMTV-cNeu Mice
Scientists showed that despite their morphologic symmetry, left versus right mammary glands in wild-type mice have baseline differences in gene expression that are L-R independently regulated during pubertal development, including genes that regulate luminal progenitor cell renewal, luminal cell differentiation, mammary tumorigenesis, tamoxifen sensitivity and chemotherapeutic resistance. [Oncogene] Abstract

A Genomic Analysis of Mouse Models of Breast Cancer Reveals Molecular Features of Mouse Models and Relationships to Human Breast Cancer
The degree to which mouse models model human breast cancer and are reflective of the human heterogeneity has yet to be demonstrated with gene expression studies on a large scale. To this end, researchers have built a database consisting of 1,172 mouse mammary tumor samples from 26 different major oncogenic mouse mammary tumor models. [Breast Cancer Res] Full Article | Press Release

Mesenchymal Precursor Cells Maintain the Differentiation and Proliferation Potentials of Breast Epithelial Cells
Investigators isolated and characterized human breast epithelial and mesenchymal precursors from reduction mammoplasty tissue and tagged them with lentiviral vectors. [Breast Cancer Res] Abstract |  Full Article

Obatoclax Analog SC-2001 Inhibits STAT3 Phosphorylation through Enhancing SHP-1 Expression and Induces Apoptosis in Human Breast Cancer Cells
Researchers examined the efficacy and drug mechanism of an obatoclax analog SC-2001, a novel STAT3 inhibitor, in human breast cancer cells. STAT3-regulated proteins, including Mcl-1, survivin, and cyclin D1, were repressed by SC-2001. [Breast Cancer Res Treat] Abstract

Phenotypic Plasticity in Normal Breast Derived Epithelial Cells
Explant culture was utilized to isolate cells from pieces of breast tissue. Selective media and trypsinization were employed to select either epithelial cells or stromal cells. The primary, non-transformed epithelial cells were characterized by immunohistochemistry, flow cytometry, and in vitro cell culture. [BMC Cell Biol]
Abstract | Full Article

Age-Related Dysfunction in Mechanotransduction Impairs Differentiation of Human Mammary Epithelial Progenitors
Multipotent progenitors from women aged <30 years were exposed to a physiologically relevant range of matrix elastic modulus (stiffness). Increased stiffness causes a differentiation bias towards myoepithelial cells while reducing production of luminal cells and progenitor maintenance. [Cell Rep]
Abstract | Full Article | Graphical Abstract | Press Release


Final Report of the Phase I/II Clinical Trial of the E75 (nelipepimut-S) Vaccine with Booster Inoculations to Prevent Disease Recurrence in High-Risk Breast Cancer Patients
E75 is a human leukocyte antigen-A2/A3-restricted immunogenic peptide derived from the HER2 protein. Investigators conducted phase I/II clinical trials vaccinating breast cancer patients with nelipepimut-S and GM-CSF in the adjuvant setting to prevent disease recurrence. [Ann Oncol] Abstract

Significant Survival Impact of MACC1 Polymorphisms in HER2 Positive Breast Cancer Patients
Researchers aimed to investigate the influence of metastasis-associated in colon cancer-1 (MACC1) polymorphisms on event-free and overall survival in patients with human epidermal growth factor 2 (HER2)-positive breast cancer. [Eur J Cancer] Abstract

Heading to ISSCR 2014 in Vancouver?
Come Visit Connexon Creative at Booth #507 and Enter to Win $100 Amazon Gift Card!

Dissociation Enzymes For Optimized Human Mammary Tissue Dissociation and Culture
The Impact of Tumor Stroma on Drug Response in Breast Cancer
The authors focus on the modulatory effect of the tumor microenvironment on the differing response of breast cancer subtypes to targeted drugs and chemotherapy. [Semin Cancer Biol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
A Few Circulating Cancer Cells Could Cue Risk of Metastases
A simple noninvasive blood test matched with state-of-the-art molecular imaging of individual cells could help oncologists understand their patients’ chances of survival. Researchers took breast cancer cells isolated from the blood of small animal models and imaged them using radioluminescence microscopy and SCAR along with a common molecular imaging radiotracer called F-18 fluorodeoxyglucose. [Press release from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) discussing research presented at the SNMMI 2014 Annual Meeting, St. Louis] Press Release

Eisai Presents Data on Halaven® from Pooled Analysis of Over 1,800 Advanced Breast Cancer Patients
Eisai Co., Ltd. announced that it has presented data from a pooled analysis of two randomized open-label Phase III clinical studies on the use of Halaven®, a non-taxane microtubule dynamics inhibitor, in patients with locally advanced or metastatic breast cancer who had progressed after receiving prior therapy including an anthracycline and a taxane in either the adjuvant or metastatic setting. [Press release from Eisai Co., Ltd. discussing research presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
Legacy Cancer Institute Offering Vaccine Trial to Target Breast Cancer Recurrence
Legacy Cancer Institute’s clinical trial is aimed at preventing recurrence in women who have survived triple negative breast cancer, or who have had lymph node involvement. Legacy Cancer Institute enters the study in Phase II after results from Phase I showed a 50 percent reduction in recurrence for patients with triple negative breast cancer. [Legacy Health] Press Release

Immune Design Announces Treatment of First Patient in Phase I Clinical Trial of LV305 Immuno-Oncology Agent
Immune Design announced treatment of the first patient in a Phase I clinical trial of LV305, an immuno-oncology investigational agent from the company’s DCVex™ lentiviral vector platform. [Immune Design Corp] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Best of American Society of Clinical Oncology (ASCO) Chicago
August 15-16, 2014
Chicago, United States

Visit our events page to see a complete list of events in the mammary cell community.
NEW PhD Research Fellow – Molecular Cancer Research (Norwegian University of Science and Technology)

NEW Postdoctoral Fellow – Cancer Biology (The University of Queensland)

NEW Postdoctoral Fellow – Tumor Microenvironment of Bone Metastasis of Breast and Prostate Cancer (University of Edinburgh)

Postdoctoral Scholar – Cancer and RNA Research (Northwestern University)

PhD Scholarship – Breast Cancer (Royal College of Surgeons in Ireland)

Postdoctoral Research Associates – Pattern Formation during Branching Morphogenesis of the Mammary Gland (Princeton University)

Postdoctoral Positions – Breast Cancer, Mouse Models, Tumor Microenvironment (National Cancer Institute)

Postdoctoral Position – Breast Cancer Research (University of Oklahoma Health Sciences Center)

Postdoctoral Fellow – Mechanisms that Contribute to Metastases of Breast Cancer Cells (Icahn School of Medicine at Mount Sinai)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Mammary Cell News: Archives | Events | Contact Us